SCHEMBL14692425

SCHEMBL14692425

Cn1c(=O)n(CCN)c(=O)c2ccccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC1 P07992 1/20 0.56
FEN1 P39748 1/20 0.56
ERCC4 Q92889 1/20 0.56
TNF P01375 1/20 0.56
HDAC1 Q13547 2/20 0.55
SLC9A1 P19634 1/20 0.54
PGR P06401 1/20 0.53
TSHR P16473 3/20 0.51
KDM4E B2RXH2 2/20 0.51
HSD17B10 Q99714 2/20 0.51
LMNA P02545 1/20 0.51
MAPK1 P28482 1/20 0.51
HTT P42858 1/20 0.51
NPEPPS P55786 1/20 0.50
ALDH1A1 P00352 2/20 0.49
TDP1 Q9NUW8 2/20 0.47
AGER Q15109 1/20 0.47
RXRA P19793 1/20 0.47
MAPK8 P45983 1/20 0.45
NPC1 O15118 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7852147 0.83 ERCC1 (0.56) ERCC1FEN1ERCC4TNFHDAC1
SCHEMBL6510771 0.83 ERCC1 (0.60) ERCC1FEN1ERCC4TNFHDAC1
SCHEMBL6363131 0.83 MAPK8 (0.64) ERCC1FEN1ERCC4TNFSLC9A1
SCHEMBL16822023 0.82 CYP1A2 (0.59) TSHRLMNAALDH1A1AGERNPC1
SCHEMBL25936308 0.82 TOP2A (0.58) ERCC1FEN1ERCC4TNFHDAC1
SCHEMBL14560541 0.82 PGR (0.67) ERCC1FEN1ERCC4TNFHDAC1
SCHEMBL5039317 0.81 ERCC1 (0.57) ERCC1FEN1ERCC4TNFHDAC1
SCHEMBL11884498 0.81 ERCC1 (0.62) ERCC1FEN1ERCC4TNFHDAC1
SCHEMBL6803416 0.81 TNF (0.60) ERCC1FEN1ERCC4TNFHDAC1
SCHEMBL5036947 0.80 TNF (0.62) ERCC1FEN1ERCC4TNFHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8916573-B2 Quinazoline-2,4-dione derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2014-12-23 US disclosed
US-20140171425-A1 QUINAZOLINE-2,4-DIONE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2014-06-19 US disclosed
EP-2742042-A1 QUINAZOLINE-2,4-DIONE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2014-06-18 EP disclosed
WO-2013021363-A1 QUINAZOLINE-2,4-DIONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171425-A1 QUINAZOLINE-2,4-DIONE DERIVATIVES NQO2, H1-3, H1-0 ERCC1 3794/4885FEN1 3286/4885ERCC4 3158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.